FLEXBUMIN ® 25% [Albumin (Human)] is indicated for hypovolemia, hypoalbuminemia, cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN). FLEXBUMIN 25% [Albumin (Human)] is indicated for reversing hypovolemia. When hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 25% albumin should be used. 4,6 FLEXBUMIN 25% is indicated for patients with hypoal...
For intravenous use only. The dose required depends on the patient's body weight, severity of injury/illness and on continuing fluid and protein losses. Adjust the concentration, dosage and infusion rate to the patient's individual requirements. Use adequacy of circulating blood volume, not plasma albumin levels, to determine the dose required. Refer to Table 1 for recommended doses. Do not exceed 2 g of albumin p...
FLEXBUMIN 25% is supplied in a single-dose plastic container: Plastic Container NDC Number Carton NDC Number Grams Protein and Fill Size NDC 0944-0493-03 (quantity of 1) NDC 0944-0493-01 (quantity of 12) 12.5 grams in a 50 mL plastic container NDC 0944-0493-04 (quantity of 1) NDC 0944-0493-02 (quantity of 6) 25 grams in a 100 mL plastic container Storage Room temperature: not to exceed 25°C (77°F). Protect from fr...
www.fda.gov/medwatchFLEXBUMIN® 25% [Albumin (Human)] is indicated for hypovolemia, hypoalbuminemia, cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).
FLEXBUMIN 25% [Albumin (Human)] is indicated for reversing hypovolemia. When hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 25% albumin should be used.4,6
FLEXBUMIN 25% is indicated for patients with hypoalbuminemia resulting from one or more of the following:5
FLEXBUMIN 25% is indicated for patients with hypoalbuminemia accompanying severe injuries, infections or severe pancreatitis that cannot be quickly reversed and nutritional supplements fail to restore serum albumin levels.
Burns
After the first 24 hours, FLEXBUMIN 25% is indicated, in conjunction with appropriate crystalloid therapy, for the treatment of oncotic deficits following extensive burns and to replace the protein loss which accompanies any severe burn.4,6
Adult Respiratory Distress Syndrome (ARDS)
FLEXBUMIN 25% is indicated, in conjunction with diuretics, to correct interstitial pulmonary edema and hypoproteinemia associated with ARDS.4
Nephrosis
FLEXBUMIN 25% is indicated for treatment of edema in patients with severe nephrosis who are receiving steroids and/or diuretics.
Preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass surgery. FLEXBUMIN 25% is indicated as a component of the pump priming during cardiopulmonary bypass procedures.4,6,12
FLEXBUMIN 25% is indicated for infants with severe HDN to bind and detoxify unconjugated bilirubin.
Albumin is not indicated as an intravenous nutrient.
For intravenous use only.
The dose required depends on the patient's body weight, severity of injury/illness and on continuing fluid and protein losses. Adjust the concentration, dosage and infusion rate to the patient's individual requirements. Use adequacy of circulating blood volume, not plasma albumin levels, to determine the dose required. Refer to Table 1 for recommended doses.
Do not exceed 2 g of albumin per kg of body weight for the daily dose. Do not exceed 1 mL/min for patients with normal blood volume. More rapid administration can cause circulatory overload and pulmonary edema11 [see Warnings and Precautions (5.2)].
| Indication | Dose |
|---|---|
| Hypovolemic Shock | Infants and young children: 2.5 to 5 mL per kg body weight. Older children and adults: initial dose 100 to 200 mL. Repeat after 15 to 30 minutes if response is not adequate. |
| Hypoalbuminemia | Calculate the body albumin compartment to be 80 to 100 mL per kg body weight. Do not exceed a daily dose of 2 g of albumin per kg of body weight. |
| Burns | The dosage should be determined according to the patient's condition and response to treatment after the first 24 hours. |
| Hemolytic disease in newborn | 1 g per kilogram body weight prior to or during exchange transfusion.12 |
Hypovolemia
Reversing hypovolemia depends largely upon its ability to draw interstitial fluid into the circulation. It is most effective in patients who are well hydrated. Use 5% protein solutions or dilute 25% albumin with crystalloid solutions in the absence of adequate or excessive hydration.
Hypoalbuminemia
If albumin deficit is the result of excessive protein loss, the effect of FLEXBUMIN 25% will be temporary unless the underlying disorder is reversed.
CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of fluid from the secondary container is complete.
FLEXBUMIN 25% is a solution containing 25 g of albumin per 100 mL.
Hypersensitivity reactions (including anaphylactic reactions) have been observed. Discontinue administration immediately if a hypersensitivity reaction (including anaphylactic type reactions) is suspected. In case of shock, implement standard medical treatment for shock.
Under conditions where hypervolemia and/or hemodilution may occur, adjust dose and rate of infusion to the patient's volume status. Monitor coagulation and hematology parameters when comparatively large volumes are replaced. Ensure adequate substitution of other blood constituents (coagulation factors, platelets, and erythrocytes). Monitor electrolyte status to maintain the electrolyte balance.
Discontinue administration at the first clinical signs of cardiovascular overload (e.g., headache, dyspnea, jugular venous distention, rales and abnormal elevations in systemic or central venous blood pressure).
Conditions that pose increased risk of hypervolemia and/or hemodilution include but are not limited to:
Closely monitor hemodynamic parameters after administering FLEXBUMIN 25% for evidence of cardiac or respiratory failure, renal failure, or increasing intracranial pressure.
Monitor blood pressure in trauma patients and postoperative surgery patients resuscitated with FLEXBUMIN 25% in order to detect re-bleeding secondary to clot disruption.
Do not dilute FLEXBUMIN 25% with Sterile Water for Injection as this can cause hemolysis in recipients. There exists a risk of potentially fatal hemolysis and acute renal failure from the use of Sterile Water for Injection as a diluent for Albumin (Human) in concentrations of 20% or higher [see Dosage and Administration (2.2)].
FLEXBUMIN 25% is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD, have ever been identified for licensed albumin.
All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327). The physician should discuss the risks and benefits of this product with the patient.
The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema.
No sponsor initiated clinical studies have been conducted with FLEXBUMIN 25%.
The following adverse reactions have been identified during postapproval use of FLEXBUMIN 25%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported in the postapproval use of FLEXBUMIN 25%:
Risk Summary
No human or animal data are available to indicate the presence or absence of drug-associated risk. It is not known whether FLEXBUMIN 25% can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.
Risk Summary
No human or animal data are available to indicate the presence or absence of drug-associated risk. It is not known whether FLEXBUMIN 25% is excreted in human milk.
The safety of albumin solutions has been demonstrated in children provided the dose is appropriate for body weight; however, the safety of FLEXBUMIN 25% has not been evaluated in sponsor conducted pediatric studies.
No human or animal data.
Hypervolemia may occur if the dosage and rate of infusion are too high [see Warnings and Precautions (5.2)].
FLEXBUMIN 25% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. Each 100 mL contains 25 g of albumin. It has been adjusted to physiological pH with sodium bicarbonate and/or sodium hydroxide and stabilized with N-acetyltryptophan (0.02M) and sodium caprylate (0.02M). The sodium content is 145 ± 15 mEq/L. FLEXBUMIN 25% contains no preservative and none of the coagulation factors found in fresh whole blood or plasma. FLEXBUMIN 25% is a transparent or slightly opalescent solution which may have a greenish tint or may vary from a pale straw to an amber color and is clear of particulate matter.
FLEXBUMIN 25% is manufactured from human plasma by the modified Cohn-Oncley cold ethanol fractionation process, which includes a series of cold-ethanol precipitation, centrifugation and/or filtration steps followed by pasteurization of the final product at 60 ± 0.5°C for 10 to 11 hours. This process accomplishes both purification of albumin and reduction of viruses.
In vitro studies demonstrate that the manufacturing process for FLEXBUMIN 25% provides for effective viral reduction. These viral reduction studies, summarized in Table 2, demonstrate viral clearance during the manufacturing process for FLEXBUMIN 25%.
These studies indicate that specific steps in the manufacturing of FLEXBUMIN 25% are capable of eliminating/inactivating a wide range of relevant and model viruses. Since the mechanism of virus elimination/inactivation by fractionation and by heating steps is different, the overall manufacturing process of FLEXBUMIN 25% is effective in reducing viral load.
| Process Step | Viral Reduction Factor (log10) | |||||
|---|---|---|---|---|---|---|
| Lipid Enveloped | Non-Enveloped | |||||
| HIV-1 | Flaviviridae | PRV | HAV | Parvoviridae | ||
| BVDV | WNV | MMV | ||||
| Processing of Fraction I + II + III/II + III supernatant to Fraction IV4 Cuno 70C filtrate† | >4.9 | >4.8 | >5.7 | >5.5 | >4.5 | 3.0 |
| Pasteurization | >7.8 | >6.5 | n.d.‡ | >7.4 | 3.2 | 1.6§ |
| Mean Cumulative Reduction Factor, log10 | >12.7 | >11.3 | >5.7 | >12.9 | >7.7 | 4.6 |
* Human immunodeficiency virus, type 1 (HIV-1) both as a target virus and model for HIV-2 and other lipid-enveloped RNA viruses; bovine viral diarrhea virus (BVDV), a model for lipid-enveloped RNA viruses, such as hepatitis C virus (HCV); West Nile Virus (WNV), a target virus and model for other similar lipid-enveloped RNA viruses; pseudorabies virus (PRV), a model for other lipid-enveloped DNA viruses such as hepatitis B virus (HBV); mice minute virus (MMV), models for non-enveloped DNA viruses such as human parvovirus B1910; and hepatitis A virus (HAV), a target virus and a model for other non-enveloped RNA viruses.
† Other Albumin fractionation process steps (processing of cryo-poor plasma to Fraction I + II + III/II + III supernatant and processing of Fraction V suspension to Cuno 90LP filtrate) showed virus reduction capacity in in vitro viral clearance studies. These process steps also contribute to the overall viral clearance effectiveness of the manufacturing process. However, since the mechanism of virus removal is similar to that of this particular process step, the viral inactivation data from other steps were not used in the calculation of the Mean Cumulative Reduction Factor.
‡ n.d. = not determined.
§ Recent scientific data suggests that the actual human parvovirus B19 (B19V) is far more effectively inactivated by pasteurization than indicated by model virus data.10
The likelihood of the presence of viable hepatitis viruses has been minimized by testing the plasma at three stages: for the presence of hepatitis viruses, by fractionation steps with demonstrated virus removal capacity and by heating the product for 10 hours at 60°C. This procedure has been shown to be an effective method of inactivating hepatitis virus in albumin solutions even when those solutions were prepared from plasma known to be infective.1,2,3
Albumin is responsible for 70 to 80% of the colloid osmotic pressure of normal plasma, thus making it useful in regulating the volume of circulating blood.4,5,6 Albumin is also a transport protein and binds naturally occurring, therapeutic and toxic materials in the circulation.5,6
FLEXBUMIN 25% is osmotically equivalent to approximately five times its volume of human plasma. When injected intravenously, 25% albumin will draw about 3.5 times its volume of additional fluid into the circulation within 15 minutes, except when the patient is markedly dehydrated. This extra fluid reduces hemoconcentration and blood viscosity. The degree and duration of volume expansion depends upon the initial blood volume. In patients with decreased blood volume, the effect of infused albumin can persist for many hours; however, in patients with normal blood volume, the duration will be shorter.7,8,9
Total body albumin is estimated to be 350 g for a 70 kg patient, with more than 60% located in the extravascular fluid compartment. The half-life of albumin is 15 to 20 days with a turnover of approximately 15 g per day.5
The minimum plasma albumin level necessary to prevent or reverse peripheral edema is unknown. It is recommended that plasma albumin levels be maintained at approximately 2.5 g/dL. This concentration provides a plasma oncotic pressure value of 20 mmHg.4
FLEXBUMIN 25% is supplied in a single-dose plastic container:
| Plastic Container NDC Number | Carton NDC Number | Grams Protein and Fill Size |
|---|---|---|
| NDC 0944-0493-03 (quantity of 1) | NDC 0944-0493-01 (quantity of 12) | 12.5 grams in a 50 mL plastic container |
| NDC 0944-0493-04 (quantity of 1) | NDC 0944-0493-02 (quantity of 6) | 25 grams in a 100 mL plastic container |
Storage
Room temperature: not to exceed 25°C (77°F). Protect from freezing.
Takeda Pharmaceuticals U.S.A., Inc.
Cambridge, MA 02142
U.S. License No. 1898
FLEXBUMIN is a registered trademark of Baxalta Incorporated.
Takeda and 
©2024 Takeda Pharmaceutical Company Limited. All rights reserved.
FLX371
Albumin (Human)
Flexbumin®
25% USP/50ml
Solution for infusion
Takeda
Single-Dose Container
50 mL
NDC 0944-0493-03
Code 2G0201
Each 50 mL contains: 12.5 g albumin from venous plasma in buffered diluent and
is osmotically equivalent to 250 mL of normal human plasma. It has been stabilized
with sodium caprylate and N-acetyltryptophan and heated for 10 hours at 60°C.
The sodium content is 145 ± 15 mEq/L. Contains no preservative. See accompanying
package insert.
Cautions: In patients with marked dehydration, additional fluids must accompany
or follow administration of this product. Check for minute leaks by squeezing bag
firmly. If leaks are found, discard bag as sterility may be impaired. Do not use if
turbid. Do not begin administration more than 4 hours after the container has
been entered. Discard partially used container. The patient and physician should
discuss the risks and benefits of this product.
Rx Only
Recommended storage: Store at room temperature, not to exceed 25°C (77°F).
Protect from freezing.
FLEXBUMIN is a registered trademark of Baxalta Incorporated.
Takeda and
Pharmaceutical Company Limited.
©2024 Takeda Pharmaceutical Company Limited. All rights reserved.
Takeda Pharmaceuticals U.S.A., Inc.
Cambridge, MA 02142 U.S. License No. 1898
PL 2501 Plastic 0762486
Albumin (Human)
Flexbumin®
25% USP/50ml
Solution for infusion
Takeda
12 x 50 mL
Single-Dose
Containers
NDC 0944-0493-01
Code 2G0201
Albumin (Human)
Flexbumin®
25% USP/100ml
Solution for infusion
Takeda
Single-Dose Container
100 mL
NDC 0944-0493-04
Code 2G0012
Each 100 mL contains: 25 g albumin from venous plasma in
buffered diluent and is osmotically equivalent to 500 mL of normal
human plasma. It has been stabilized with sodium caprylate
and N-acetyltryptophan and heated for 10 hours at 60°C. The
sodium content is 145 ± 15 mEq/L. Contains no preservative. See
accompanying package insert.
Cautions: In patients with marked dehydration, additional fluids must
accompany or follow administration of this product. Check for minute
leaks by squeezing bag firmly. If leaks are found, discard bag as sterility
may be impaired. Do not use if turbid. Do not begin administration
more than 4 hours after the container has been entered. Discard
partially used container. The patient and physician should discuss the
risks and benefits of this product.
Rx Only
Recommended storage: Store at room temperature, not to exceed 25°C
(77°F). Protect from freezing.
FLEXBUMIN is a registered trademark of Baxalta Incorporated.
Takeda and
Pharmaceutical Company Limited.
©2024 Takeda Pharmaceutical Company Limited. All rights
reserved.
Takeda Pharmaceuticals U.S.A., Inc.
Cambridge, MA 02142 U.S. License No. 1898
PL 2501 Plastic 0762490
Albumin (Human)
Flexbumin®
25% USP/100ml
Solution for infusion
Takeda
6 x 100 mL
Single-Dose
Containers
NDC 0944-0493-02
Code 2G0012
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1741380 | albumin human 25 % in 100 ML Injection | PSN | 17 |
| 1741375 | albumin human 25 % in 50 ML Injection | PSN | 17 |
| 1742403 | FLEXBUMIN 25 % in 100 ML Injection | PSN | 17 |
| 1742401 | FLEXBUMIN 25 % in 50 ML Injection | PSN | 17 |
| 1742403 | 100 ML albumin human, USP 250 MG/ML Injection [Flexbumin] | SBD | 17 |
| 1742401 | 50 ML albumin human, USP 250 MG/ML Injection [Flexbumin] | SBD | 17 |
| 1741380 | 100 ML albumin human, USP 250 MG/ML Injection | SCD | 17 |
| 1741375 | 50 ML albumin human, USP 250 MG/ML Injection | SCD | 17 |
| 1741375 | albumin human 12.5 GM per 50 ML Injection | SY | 17 |
| 1741380 | albumin human 25 % per 100 ML Injection | SY | 17 |
| 1741375 | albumin human 25 % per 50 ML Injection | SY | 17 |
| 1741380 | albumin human 25 GM per 100 ML Injection | SY | 17 |
| 1742401 | Flexbumin 12.5 GM per 50 ML Injection | SY | 17 |
| 1742403 | Flexbumin 25 % per 100 ML Injection | SY | 17 |
| 1742401 | Flexbumin 25 % per 50 ML Injection | SY | 17 |
| 1742403 | Flexbumin 25 GM per 100 ML Injection | SY | 17 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ALBUMIN (HUMAN) Pharmacologic Class Indexing | 1 | Indexing - Pharmacologic Class | 20120517 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0944-0493-01 | FLEXBUMIN | 12 in 1 CARTON | SOLUTION | 12 | 17 | |
| 0944-0493-02 | FLEXBUMIN | 6 in 1 CARTON | SOLUTION | 6 | 17 | |
| 0944-0493-03 | FLEXBUMIN | 50 mL in 1 BAG | SOLUTION | 50 | 17 | |
| 0944-0493-04 | FLEXBUMIN | 100 mL in 1 BAG | SOLUTION | 100 | 17 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0944-0493-01 | ML - Milliliter | 0944-0493 | a88a1257-57d4-4d9f-a61a-f5806367e6e7 | 1 | 2012-07-24 |
| 0944-0493-02 | ML - Milliliter | 0944-0493 | 0f322d7d-2ff7-4a46-b1c0-f43a93fb62f3 | 1 | 2012-07-24 |
| 0944-0493-03 | ML - Milliliter | 0944-0493 | bb99283c-302f-426c-b2d2-bb3bc95421e9 | 1 | 2024-02-14 |
| 0944-0493-04 | ML - Milliliter | 0944-0493 | a9527945-e3ad-4bc7-8a8b-553a00ab954f | 1 | 2024-04-05 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALBUMIN HUMAN | ACTIVE INGREDIENT | ZIF514RVZR | 4 | |
| ALBUMIN HUMAN | ACTIVE MOIETY | ZIF514RVZR | 4 | |
| SODIUM ACETYLTRYPTOPHANATE | INACTIVE INGREDIENT | 3EN9H0M2FX | 4 | |
| SODIUM CAPRYLATE | INACTIVE INGREDIENT | 9XTM81VK2B | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0944-0493 | 0944-0493-03, 0944-0493-01, 0944-0493-04, 0944-0493-02 |
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 101452 | Buminate, Flexbumin | Albumin (Human) | 351(a) | Rx | 2026-09-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ALBUMIN HUMAN | ZIF514RVZR | ACTIB |
| N-ACETYL-DL-TRYPTOPHAN SODIUM | 3EN9H0M2FX | IACT |
| SODIUM CAPRYLATE | 9XTM81VK2B | IACT |
| SODIUM CATION | LYR4M0NH37 | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ALBUMINEX | ALBUMIN HUMAN | BPL | 8428d373-f4b1-4e3b-bb19-ea89048f7c79 | 2024-12-31 | Warnings, Adverse reactions | ALBUMIN HUMAN |
| ALBUMINEX | ALBUMIN HUMAN | BPL | 167f48d0-8ae5-4f7e-b050-9673dad78acc | 2024-12-31 | Warnings, Adverse reactions | ALBUMIN HUMAN |
Adverse event summaries are temporarily unavailable. Other product information remains available.